Healthcare
Zenith Capital Corp.(ZHCLF)
Live Price
Offline$0.02
-60.00% today
1Y Change
-96.00%
Window
Jun 23, 2025 → Jun 15, 2026
- Market Cap
- $10.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +31.2%
- Dividend Yield
- 0.0%
Coverage: 240 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zenith Capital Corp. (ZHCLF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.02 and down 96.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +31.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +31.2%, free cash flow +100.0% with operating margin -886.4% and ROIC 0.0%. Valuation already assumes a fairly strong business story at price/sales 17.6. Stock Foundry combines ZHCLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-886.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +31.2%, while operating margin sits near -886.4%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZHCLF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZHCLF Max Drawdown
-99.83%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZHCLF and SPY.
Company Overview
Zenith Capital Corp.
Other OTC
Zenith Capital Corp. is a biotechnology investment company, which engages in the discovery and development of novel therapeutics. The company was founded by Donald J. McCaffrey on April 10, 2013 and is headquartered in Calgary, Canada.
- Leadership
- Donald J. McCaffrey
- IPO Date
- May 28, 2021
- Street Address
- 4820 Richard Road SW
- Mailing
- Calgary, AB, T3E 6L1
- Region
- Calgary, AB, CA
- Reporting Currency
- USD
- Investor Line
- 587 390 7865
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 17.6
- Price/Book
- —
Growth
- Revenue
- 0.0%
- EPS
- +31.2%
- Free Cash Flow
- +100.0%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -886.4%
- Net Margin
- -1406.2%
- ROE
- 0.0%
- ROIC
- 0.0%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- —
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.